2024 ASCO Highlights: Focus on HER2+ Breast Cancer (Part 3)

Drs. Claudine Isaacs and Filipa Lynce conclude their discussion on the highlights of ASCO 2024 Annual Meeting, with a focus on HER2+ breast cancer. They discussed results from the Destiny Breast 07 trial, highlighting the efficacy of TDXD alone and in combination with pertuzumab in first-line treatment of HER2-positive breast cancer. The study showed high overall response rates and promising progression-free survival rates with both regimens. ILD was identified as a concerning toxicity. Additionally, an upcoming presentation on the ACE Breast-02 study, which evaluated a novel antibody-drug conjugate against lapatinib and capecitabine in heavily pre-treated HER2-positive patients, was discussed. This novel ADC showed improved progression-free survival compared to the standard regimen but had a different toxicity profile.